1. Home
  2. IOVA vs KOD Comparison

IOVA vs KOD Comparison

Compare IOVA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$7.41

Market Cap

6.7B

Sector

Health Care

ML Signal

N/A

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

N/A

Current Price

$99.32

Market Cap

6.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IOVA
KOD
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
6.2B
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
IOVA
KOD
Price
$7.41
$99.32
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$14.50
★ $130.17
AVG Volume (30 Days)
★ 12.8M
730.9K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 14.84
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$58.86
N/A
Revenue Next Year
$41.86
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$20.38
52 Week High
$15.37
$112.31

Technical Indicators

Market Signals
Indicator
IOVA
KOD
Relative Strength Index (RSI) 31.10 52.43
Support Level $3.57 $90.50
Resistance Level $9.36 $103.67
Average True Range (ATR) 0.57 6.74
MACD -0.13 -1.78
Stochastic Oscillator 4.34 32.28

Price Performance

Historical Comparison
IOVA
KOD

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: